Retatrutide appears to be a new pharmaceutical in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By boosting these https://adreaymbf037766.aioblogs.com/89058991/tirzepatide-a-promising-new-treatment-for-obesity